Roche has bolstered its R&D pipeline in oncology and neuroscience with a pair of partnerships with Orionis Biosciences and PeptiDream, parting with upfront cash of $87 million for projects in the hot areas of molecular glues and radiotherapy-delivering drugs.The deal with Orionis has a top-line value of $2 billion, with $47 million of that paid […]

Author